 "Aurobindo Pharma")
Indian generics company Aurobindo Pharma Limited on Wednesday said the opportunity of launching new generic drugs in the US market would be inexhaustible at least for the next five years.
With sales growth in the increasingly competitive US market largely dependent on the number of new product launches, a robust pipeline of new drug filings becomes a basic prerequisite for a generics drug player to keep its business growing year after year.
Responding to an analyst's question on how many more years would the company be able to file the abbreviated new drug applications (ANDAs) for approval of new launches at the
